Literature DB >> 23231025

Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.

Gillian M Keating1.   

Abstract

Ingenol mebutate is the main active constituent of sap from the plant Euphorbia peplus, which has traditionally been used as a home remedy for various skin conditions. Ingenol mebutate gel is approved in the US, EU, Australia and Brazil for the topical treatment of actinic keratosis. A short course of field-directed therapy with topical ingenol mebutate gel was effective in the treatment of actinic keratoses on the face or scalp (ingenol mebutate gel 0.015% once daily for 3 consecutive days) and on the trunk or extremities (ingenol mebutate gel 0.05% once daily for 2 consecutive days), according to the results of four randomized, double-blind, vehicle-controlled, multicentre studies. Significantly higher complete clearance rates (primary endpoint) and partial clearance rates were seen at day 57 in patients receiving ingenol mebutate gel than in those receiving vehicle gel. Treatment with ingenol mebutate gel was generally associated with sustained clearance of actinic keratoses in the longer term. Topical ingenol mebutate gel was generally well tolerated in the treatment of patients with actinic keratoses on the face or scalp and on the trunk or extremities. Application-site conditions were the most commonly occurring adverse events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23231025     DOI: 10.2165/11470090-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  15 in total

Review 1.  Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference.

Authors:  James Q Del Rosso
Journal:  Cutis       Date:  2011-07

Review 2.  Actinic keratoses. Differential diagnosis and treatment.

Authors:  J W Barnaby; A R Styles; C J Cockerell
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

3.  The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers.

Authors:  J R Ramsay; A Suhrbier; J H Aylward; S Ogbourne; S-J Cozzi; M G Poulsen; K C Baumann; P Welburn; G L Redlich; P G Parsons
Journal:  Br J Dermatol       Date:  2011-01-27       Impact factor: 9.302

4.  The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.

Authors:  Luowei Li; Suneet Shukla; Andrew Lee; Susan H Garfield; David J Maloney; Suresh V Ambudkar; Stuart H Yuspa
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

5.  Ingenol mebutate gel for actinic keratosis.

Authors:  Mark Lebwohl; Neil Swanson; Lawrence L Anderson; Anita Melgaard; Zhenyi Xu; Brian Berman
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.

Authors:  Greg Siller; Kurt Gebauer; Peter Welburn; Janelle Katsamas; Steven M Ogbourne
Journal:  Australas J Dermatol       Date:  2009-02       Impact factor: 2.875

7.  Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death.

Authors:  Steven M Ogbourne; Andreas Suhrbier; Brad Jones; Sarah-Jane Cozzi; Glen M Boyle; Melanie Morris; Devi McAlpine; Jenny Johns; Tania M Scott; Kirsty P Sutherland; Joy M Gardner; Thuy T T Le; Aleksandra Lenarczyk; James H Aylward; Peter G Parsons
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

8.  Characterization of the interaction of ingenol 3-angelate with protein kinase C.

Authors:  Noemi Kedei; Daniel J Lundberg; Attila Toth; Peter Welburn; Susan H Garfield; Peter M Blumberg
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

9.  Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.

Authors:  Lawrence Anderson; George J Schmieder; W Philip Werschler; Eduardo H Tschen; Mark R Ling; Dow B Stough; Janelle Katsamas
Journal:  J Am Acad Dermatol       Date:  2009-06       Impact factor: 11.527

10.  The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner.

Authors:  Peter Hampson; Dean Kavanagh; Emily Smith; Keqing Wang; Janet M Lord; G Ed Rainger
Journal:  Cancer Immunol Immunother       Date:  2008-02-12       Impact factor: 6.968

View more
  6 in total

1.  Complete chloroplast genome of Euphorbia micractina Boiss (Euphorbiaceae: Euphorbia).

Authors:  Dan Wang; Yu-Rou Dan; Ming Liu; Fu-Qiang Yin
Journal:  Mitochondrial DNA B Resour       Date:  2022-06-28       Impact factor: 0.610

2.  Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.

Authors:  Christopher G Parker; Christian A Kuttruff; Andrea Galmozzi; Lars Jørgensen; Chien-Hung Yeh; Daniel J Hermanson; Yujia Wang; Marta Artola; Steven J McKerrall; Christopher M Josyln; Bjarne Nørremark; Georg Dünstl; Jakob Felding; Enrique Saez; Phil S Baran; Benjamin F Cravatt
Journal:  ACS Cent Sci       Date:  2017-12-06       Impact factor: 14.553

3.  Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients.

Authors:  Hyun Jae Joe; Byung Ho Oh
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-03-30

4.  In vitro screening of cytotoxic activity of euphol from Euphorbia tirucalli on a large panel of human cancer-derived cell lines.

Authors:  Viviane Aline Oliveira Silva; Marcela Nunes Rosa; Aline Tansini; Renato J S Oliveira; Olga Martinho; João Paulo Lima; Luiz F Pianowski; Rui M Reis
Journal:  Exp Ther Med       Date:  2018-05-31       Impact factor: 2.447

Review 5.  Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.

Authors:  Nevena Skroza; Nicoletta Bernardini; Ilaria Proietti; Concetta Potenza
Journal:  Ther Clin Risk Manag       Date:  2018-10-04       Impact factor: 2.423

6.  Recurrent in situ melanoma successfully treated with ingenol mebutate.

Authors:  Marion Mansuy; Nazli Nikkels-Tassoudji; Jorge E Arrese; Andree Rorive; Arjen F Nikkels
Journal:  Dermatol Ther (Heidelb)       Date:  2014-04-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.